NCT03013933View on ClinicalTrials.gov

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2022

Conditions
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Given IV

DRUG

Cyclosporine

Given PO

OTHER

Pharmacokinetic Study

Correlative studies

DRUG

Verapamil

Given PO

DRUG

Verapamil Hydrochloride

Given PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03013933 - Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter